Diakonos Oncology, a clinical-stage biotechnology company leveraging proprietary dendritic cell technology to address critical and unmet therapeutic needs in late-stage and aggressive cancers, announced that it will present its latest developments at the Biotech Showcase in San Francisco, CA from January 13-15, 2025. Biotech Showcase is a premier event for private and micro-mid-cap biotechnology companies to highlight their innovation and connect with global investors and engage with executives from prominent biopharmaceutical interests. Diakonos Oncology will be represented by President and Chief Operating Officer Jay Hartenbach, who will be presenting on recent corporate milestones and research developments, including lead product DOC1021, a unique autologous dendritic cell vaccine (DCV), which will begin enrolling patients in its Phase 2 clinical trial for glioblastoma (GBM) in H1 2025 at leading treatment centers across the US. Details of the presentation are as follows: Event: Biotech… 

Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced European CE mark approval of the Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter for the treatment of cardiac arrhythmias. The Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter is an irrigated, contact-force sensing catheter powered by the TRUPULSE™ Generator, and is fully integrated with the CARTO™ 3 System for electro-anatomical mapping and for tag indexing.1 The company expects TRUPULSE™ Generator hardware compatibility in the first half of 2025. When fully approved, the platform will provide electrophysiologists with the ability to switch between radiofrequency (RF) and pulsed field (PF) energy in the same catheter they know and trust. The Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter is not currently approved in the United States. The Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter is designed on the same platform as the radiofrequency THERMOCOOL SMARTTOUCH™… 

MimiVax, Inc. and UI Pharmaceuticals have announced the successful clinical manufacture of SurVaxM, a novel immunotherapeutic vaccine targeting Glioblastoma (GBM), at UIP’s recently qualified $26M sterile manufacturing facility. This collaboration combines MimiVax’s innovative research with UIP’s expertise in formulation development and sterile production, accelerating the path to potentially transformative therapies for patients. About SurVaxM SurVaxM is a groundbreaking immunotherapeutic targeting survivin, a cell-survival protein prevalent in glioblastomas and many other cancers. This innovative immunotherapy is engineered to stimulate a patient’s immune system to recognize survivin-expressing cancer cells as foreign, thereby controlling tumor growth and recurrence. Currently, SurVaxM is being evaluated in a randomized Phase 2b clinical trial for glioblastoma at 11 leading cancer centers across the United States. Additional clinical trials are exploring its potential in multiple myeloma, neuro-endocrine tumors (NET), and pediatric relapsed high-grade glioma. MimiVax’s Glioblastoma treatment using… 

Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau.No treatment-related severe adverse events (AEs), with only 4% discontinuation rate due to AEs, same as placebo.Enrollment opening for its COMO-1 Phase 2b dose-finding study to read out Q4 2025